South America Intravenous Immunoglobulin Market Forecast to 2028

Report Code : BMIRE00027595 | Region : LAMEA | Industry : Pharmaceuticals | Published Date : 06/Dec/2022
South America Intravenous Immunoglobulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Carmine, Anthocyanins, Caramel, Curcumin, Annatto, Carotenoids, Chlorophyll, and Others), Form (Liquid & Gel and Powder), and Application (Bakery and Confectionery, Dairy and Frozen Desserts, Beverages, Sauces; Dressings; and Condiments, RTC and RTE Products, Meat; Poultry and Seafood, and Others)

The intravenous immunoglobulin market in SAM is expected to grow from US$ 783.22 million in 2022 to US$ 1,167.28 million by 2028. It is estimated to grow at a CAGR of 6.9% from 2022 to 2028.

Increasing Geriatric Population

Many of the patients treated with IVIG are above the age of 60 years. With aging, the ability to produce T-cells to fight diseases gets significantly reduced. Thus, an older person’s body is easily prone to several infections and diseases, which increases the demand for immune therapies that involve the use of IVIg. Thus, the increase in the geriatric population across the region is bolstering the intravenous immunoglobulin market.

Market Overview

The SAM intravenous immunoglobulin market is segmented into Brazil, Argentina, and the Rest of SAM. The region held the smallest portion of the market in the global analysis. The intravenous immunoglobulin market in the region is expected to have growth opportunities during the forecast period. The intravenous immunoglobulin market in the SAM region is expected to grow, owing to increased cases of autoimmune diseases and immunodeficiencies, surge in various research activities, increase in awareness, and rise in healthcare expenditure by the countries of the region. Brazil has made huge strides in the healthcare sector, owing to increasing healthcare expenditure. As per the International Trade Administration (ITA), Brazil is the largest healthcare market in Latin America, and it spent 9.1% of its GDP on healthcare in 2020. The intravenous immunoglobulin market in Brazil is expected to flourish, owing to factors such as surge in vaccination programs and rise in healthcare expenditure by the country.

SAM Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)

SAM Intravenous Immunoglobulin Market Segmentation

The SAM intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and country. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment registered the largest market share in 2022.

Based on application, the SAM intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment registered the largest market share in 2022. Based on distribution channel, the SAM intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment registered the largest market share in 2022. Based on end user, the SAM intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The hospitals segment registered the largest market share in 2022. Based on country, the market is segmented into Brazil, Argentina, and the Rest of SAM. Brazil dominated the market in 2022.

ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the intravenous immunoglobulin market in the region.

● ADMA Biologics, Inc.

● Bio Products Laboratory Ltd.

● CSL Behring (CSL Limited)

● Grifols, S.A.

● Kedrion S.p.A

● Octapharma AG

● Pfizer Inc.

● Prothya Biosolutions B.V.

● Shanghai RAAS

● Takeda Pharmaceutical Company Limited

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 SAM Intravenous Immunoglobulin Market – By Type

1.3.2 SAM Intravenous Immunoglobulin Market – By Application

1.3.3 SAM Intravenous Immunoglobulin Market – By Distribution Channel

1.3.4 SAM Intravenous Immunoglobulin Market – By End User

1.3.5 SAM Intravenous Immunoglobulin Market – By Country

2. SAM Intravenous Immunoglobulin Market– Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. SAM Intravenous Immunoglobulin Market – Market Landscape

4.1 Overview

4.2 SAM PEST Analysis

4.3 Expert Opinion

5. SAM Intravenous Immunoglobulin Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of Immunodeficiency Diseases

5.1.2 Increasing Geriatric Population

5.2 Market Restraints

5.2.1 Adverse Effects of Immunoglobulin Therapy

5.3 Future Trends

5.3.1 Strong Pipeline Candidates for IVIG

5.4 Impact Analysis

6. Intravenous Immunoglobulin Market– SAM Analysis

6.1 SAM Intravenous Immunoglobulin Market Revenue Forecast and Analysis

7. SAM Intravenous Immunoglobulin Market Revenue and Forecast to 2028– by Type

7.1 Overview

7.2 SAM Intravenous Immunoglobulin Market, By Type 2022 & 2028 (%)

7.3 IgG

7.3.1 Overview

7.3.2 IgG Revenue and Forecast to 2028 (US$ Million)

7.4 IgM

7.4.1 Overview

7.4.2 IgM - Revenue and Forecast to 2028 (US$ Million)

7.5 IgA

7.5.1 Overview

7.5.2 IgA - Revenue and Forecast to 2028 (US$ Million)

7.6 IgE

7.6.1 Overview

7.6.2 IgE - Revenue and Forecast to 2028 (US$ Million)

7.7 IgD

7.7.1 Overview

7.7.2 IgD - Revenue and Forecast to 2028 (US$ Million)

8. SAM Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by Application

8.1 Overview

8.2 SAM Intravenous Immunoglobulin Market, By Application 2022 & 2028 (%)

8.3 Hypogammaglobulinemia

8.3.1 Overview

8.3.2 Hypogammaglobulinemia - Market Revenue and Forecast to 2028 (US$ Million)

8.4 Chronic Inflammatory Demyelinating Polyneuropathy

8.4.1 Overview

8.4.2 Chronic Inflammatory Demyelinating Polyneuropathy - Market Revenue and Forecast to 2028 (US$ Million)

8.5 Immunodeficiency Diseases

8.5.1 Overview

8.5.2 Immunodeficiency Diseases - Market Revenue and Forecast to 2028 (US$ Million)

8.6 Myasthenia Gravis

8.6.1 Overview

8.6.2 Myasthenia Gravis - Market Revenue and Forecast to 2028 (US$ Million)

8.7 Multifocal Motor Neuropathy

8.7.1 Overview

8.7.2 Multifocal Motor Neuropathy - Market Revenue and Forecast to 2028 (US$ Million)

8.8 Idiopathic Thrombocytopenic Purpura

8.8.1 Overview

8.8.2 Idiopathic Thrombocytopenic Purpura - Market Revenue and Forecast to 2028 (US$ Million)

8.9 Inflammatory Myopathies

8.9.1 Overview

8.9.2 Inflammatory Myopathies - Market Revenue and Forecast to 2028 (US$ Million)

8.10 Specific Antibody Deficiency

8.10.1 Overview

8.10.2 Specific Antibody Deficiency - Market Revenue and Forecast to 2028 (US$ Million)

8.11 Guillain-Barre Syndrome

8.11.1 Overview

8.11.2 Guillain-Barre Syndrome - Market Revenue and Forecast to 2028 (US$ Million)

8.12 Others

8.12.1 Overview

8.12.2 Others - Market Revenue and Forecast to 2028 (US$ Million)

9. SAM Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by Distribution Channel

9.1 Overview

9.2 SAM Intravenous Immunoglobulin Market, By Distribution Channel 2022 & 2028 (%)

9.3 Hospital Pharmacy

9.3.1 Overview

9.3.2 Hospital Pharmacy - Market Revenue and Forecast to 2028 (US$ Million)

9.4 Retail Pharmacy

9.4.1 Overview

9.4.2 Retail Pharmacy - Market Revenue and Forecast to 2028 (US$ Million)

9.5 Others

9.5.1 Overview

9.5.2 Others - Market Revenue and Forecast to 2028 (US$ Million)

10. SAM Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by End User

10.1 Overview

10.2 SAM Intravenous Immunoglobulin Market, By End User 2022 & 2028 (%)

10.3 Hospitals

10.3.1 Overview

10.3.2 Hospitals - Market Revenue And Forecasts To 2028 (US$ Million)

10.4 Specialty Clinics

10.4.1 Overview

10.4.2 Specialty Clinics - Market Revenue And Forecasts To 2028 (US$ Million)

10.5 Others

10.5.1 Overview

10.5.2 Others - Market Revenue And Forecasts To 2028 (US$ Million)

11. SAM Intravenous Immunoglobulin Market Revenue and Forecasts to 2028 – Country Analysis

11.1 Overview

11.1.1 SAM: Intravenous Immunoglobulin Market, by Country, 2022 & 2028 (%)

11.1.1.1 Brazil: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)

11.1.1.1.1 Overview

11.1.1.1.2 Brazil: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)

11.1.1.1.3 Brazil: Intravenous Immunoglobulin Market, by Type, 2019–2028 (USD Million)

11.1.1.1.4 Brazil: Intravenous Immunoglobulin Market, by Application, 2019–2028 (USD Million)

11.1.1.1.5 Brazil: Intravenous Immunoglobulin Market, by Distribution Channel, 2019–2028 (USD Million)

11.1.1.1.6 Brazil: Intravenous Immunoglobulin Market, by End User, 2019–2028 (USD Million)

11.1.1.2 Argentina: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)

11.1.1.2.1 Overview

11.1.1.2.2 Argentina: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)

11.1.1.2.3 Argentina: Intravenous Immunoglobulin Market, by Type, 2019–2028 (USD Million)

11.1.1.2.4 Argentina: Intravenous Immunoglobulin Market, by Application, 2019–2028 (USD Million)

11.1.1.2.5 Argentina: Intravenous Immunoglobulin Market, by Distribution Channel, 2019–2028 (USD Million)

11.1.1.2.6 Argentina: Intravenous Immunoglobulin Market, by End User, 2019–2028 (USD Million)

11.1.1.3 Rest of SAM: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)

11.1.1.3.1 Overview

11.1.1.3.2 Rest of SAM: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)

11.1.1.3.3 Rest of SAM: Intravenous Immunoglobulin Market, by Type, 2019–2028 (USD Million)

11.1.1.3.4 Rest of SAM: Intravenous Immunoglobulin Market, by Application, 2019–2028 (USD Million)

11.1.1.3.5 Rest of SAM: Intravenous Immunoglobulin Market, by Distribution Channel, 2019–2028 (USD Million)

11.1.1.3.6 Rest of SAM: Intravenous Immunoglobulin Market, by End User, 2019–2028 (USD Million)

12. SAM Intravenous Immunoglobulin Market–Industry Landscape

12.1 Overview

12.2 Inorganic Growth Strategies

12.2.1 Overview

12.3 Organic Growth Strategies

12.3.1 Overview

13. Company Profiles

13.1 Takeda Pharmaceutical Company Limited

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Grifols, S.A.

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Pfizer Inc.

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 ADMA Biologics, Inc.

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 Bio Products Laboratory Ltd.

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 Shanghai RAAS

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 Octapharma AG

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 Kedrion S.p.A

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 CSL Behring (CSL Limited)

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

13.10 Prothya Biosolutions B.V.

13.10.1 Key Facts

13.10.2 Business Description

13.10.3 Products and Services

13.10.4 Financial Overview

13.10.5 SWOT Analysis

13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms in Intravenous Immunoglobulin Market

Table 1.             SAM Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)

Table 2.             Brazil: Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (USD Million)

Table 3.             Brazil: Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 4.             Brazil: Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

Table 5.             Brazil: Intravenous Immunoglobulin Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 6.             Argentina: Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (USD Million)

Table 7.             Argentina: Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 8.             Argentina: Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

Table 9.             Argentina: Intravenous Immunoglobulin Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 10.          Rest of SAM: Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (USD Million)

Table 11.          Rest of SAM: Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 12.          Rest of SAM: Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

Table 13.          Rest of SAM: Intravenous Immunoglobulin Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 14.          Recent Inorganic Growth Strategies in the Intravenous Immunoglobulin Market

Table 15.          Recent Organic Growth Strategies in the Intravenous Immunoglobulin Market

Table 16.          Glossary of Terms in Intravenous Immunoglobulin Market

● ADMA Biologics, Inc.

● Bio Products Laboratory Ltd.

● CSL Behring (CSL Limited)

● Grifols, S.A.

● Kedrion S.p.A

● Octapharma AG

● Pfizer Inc.

● Prothya Biosolutions B.V.

● Shanghai RAAS

● Takeda Pharmaceutical Company Limited

Reason To Buy

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the SAM intravenous immunoglobulin market.

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in the SAM intravenous immunoglobulin market, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth SAM market trends and outlook coupled with the factors driving the intravenous immunoglobulin market, as well as those hindering it

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

AVAILABLE CUSTOMIZATION RESEARCH METHODOLOGY REQUEST FOR TOC FREE SAMPLE REPORT
CHOOSE LICENCE TYPE
(South America Intravenous Immunoglobulin Market Forecast to 2028)
  • Single User Price $3,000$2,400
  • Site Price $4,000$3,200
  • Enterprise Price $5,000$4,000
Buy Now Add to Cart
REQUEST FOR TOC
SPEAK TO ANALYST
FREE SAMPLE
REPORT
INQUIRE BEFORE
BUYING
TOP
Quick Enquiry